6weo

Publication Abstract from PubMed

Interleukin-22 (IL-22) acts on epithelial cells to promote tissue protection and regeneration, but can also elicit pro-inflammatory effects, contributing to disease pathology. Here, we engineered a high-affinity IL-22 super-agonist that enabled the structure determination of the IL-22-IL-22Ralpha-IL-10Rbeta ternary complex to a resolution of 2.6 A. Using structure-based design, we systematically destabilized the IL-22-IL-10Rbeta binding interface to create partial agonist analogs that decoupled downstream STAT1 and STAT3 signaling. The extent of STAT bias elicited by a single ligand varied across tissues, ranging from full STAT3-biased agonism to STAT1/3 antagonism, correlating with IL-10Rbeta expression levels. In vivo, this tissue-selective signaling drove tissue protection in the pancreas and gastrointestinal tract without inducing local or systemic inflammation, thereby uncoupling these opposing effects of IL-22 signaling. Our findings provide insight into the mechanisms underlying the cytokine pleiotropy and illustrate how differential receptor expression levels and STAT response thresholds can be synthetically exploited to endow pleiotropic cytokines with enhanced functional specificity.

The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design.,Saxton RA, Henneberg LT, Calafiore M, Su L, Jude KM, Hanash AM, Garcia KC Immunity. 2021 Apr 13;54(4):660-672.e9. doi: 10.1016/j.immuni.2021.03.008. PMID:33852830^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.